tiprankstipranks
Orasure Technologies (OSUR)
NASDAQ:OSUR
Want to see OSUR full AI Analyst Report?

Orasure Technologies (OSUR) Price & Analysis

648 Followers

OSUR Stock Chart & Stats

$3.97
$0.00(0.00%)
At close: 4:00 PM EDT
$3.97
$0.00(0.00%)

Bulls Say, Bears Say

Bulls Say
Strong LiquidityA substantial cash reserve with no debt gives OraSure flexibility to fund Colli-Pee and Ebola 2.0 launches, absorb volatility, and invest in growth without immediate financing pressure.
Regulatory Product ProgressThese regulatory milestones expand OraSure’s addressable markets in home STI collection and Ebola testing, while strengthening its product portfolio and creating potential for recurring institutional and healthcare demand.
Sequential Recovery And Margin ImprovementImproving Diagnostics and SMS revenue, higher gross margins, and reiterated 2026 growth guidance indicate that operational initiatives and new product launches may support a durable recovery from recent weakness.
Bears Say
Severe Financial DeteriorationThe sharp revenue contraction, deeply negative operating results, and substantial cash burn show that the current cost base is not supported by demand, creating ongoing execution and funding risks if recovery is delayed.
IntelliQ Regulatory DelayThe setback removes a planned near-term growth catalyst and leaves resubmission timing uncertain, potentially delaying revenue diversification and increasing reliance on existing products and newer launches.
Demand And Public Funding ExposureSoft demand in advanced genetic and microbiome laboratories, combined with dependence on public-health budgets, exposes OraSure to structural customer concentration and funding risks that could limit the pace of recovery.

Orasure Technologies News

OSUR FAQ

What was Orasure Technologies’s price range in the past 12 months?
Orasure Technologies lowest stock price was $2.08 and its highest was $4.58 in the past 12 months.
    What is Orasure Technologies’s market cap?
    Orasure Technologies’s market cap is $267.60M.
      When is Orasure Technologies’s upcoming earnings report date?
      Orasure Technologies’s upcoming earnings report date is Nov 10, 2026 which is in 78 days.
        How were Orasure Technologies’s earnings last quarter?
        Orasure Technologies released its earnings results on Aug 05, 2026. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of -$0.27 by $0.36.
          Is Orasure Technologies overvalued?
          According to Wall Street analysts Orasure Technologies’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Orasure Technologies pay dividends?
            Orasure Technologies does not currently pay dividends.
            What is Orasure Technologies’s EPS estimate?
            Orasure Technologies’s EPS estimate is -0.23.
              How many shares outstanding does Orasure Technologies have?
              Orasure Technologies has 68,968,630 shares outstanding.
                What happened to Orasure Technologies’s price movement after its last earnings report?
                Orasure Technologies reported an EPS of $0.09 in its last earnings report, beating expectations of -$0.27. Following the earnings report the stock price went down -3.614%.
                  Which hedge fund is a major shareholder of Orasure Technologies?
                  Currently, no hedge funds are holding shares in OSUR
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Orasure Technologies

                    OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.

                    Orasure Technologies (OSUR) Earnings & Revenues

                    OSUR Earnings Call

                    Q2 2026
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The call presents a cautiously positive picture: the company delivered sequential revenue growth (9.7%), segment recoveries (Diagnostics +14.7% and SMS +9.0% sequentially), margin expansion (+120 bps GAAP gross margin) and achieved important regulatory milestones (Colli‑Pee FDA clearance and Ebola 2.0 EUA). The primary setback is the withdrawal and delay of the IntelliQ CT/NG FDA submission, alongside a non‑GAAP operating loss ($14.7M) and negative operating cash flow (‑$9.9M) this quarter. Strong cash ($161M), zero debt, insourcing and cost discipline, and clear launch plans temper the impact of the IntelliQ delay and one‑time G&A items; management reiterates revenue growth for 2026 and expects operating cash flow breakeven entering 2027.View all OSUR earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    InfuSystem Holdings
                    Stereotaxis
                    Utah Medical Products
                    Microbot Medical
                    Sanara MedTech

                    Ownership Overview

                    5.62%16.48%28.61%36.79%
                    28.61% Other Institutional Investors
                    36.79% Public Companies and
                    Individual Investors
                    Popular Stocks